Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.

What was studied

A predominantly open-label study assessed recombinant human IGF-I treatment in children with severe IGF-I deficiency due to growth-hormone insensitivity.

Who / model studied

Seventy-six children were treated for up to 12 years. The abstract does not describe a concurrent control group.

Studied dose & schedule

Seventy-six children with severe IGF-I deficiency due to growth-hormone insensitivity received recombinant human IGF-I by subcutaneous injection at 60–120 microg/kg twice daily. Treatment lasted up to 12 years in this predominantly open-label study; the abstract does not describe a separate assigned comparator arm.

What the study found

Average growth velocity increased from 2.8 to 8.0 centimeters per year in the first year, then declined but remained above baseline for up to eight years. Low blood sugar, also present before treatment, was reported in 49%. Injection-site fatty-tissue enlargement occurred in 32% and tonsil or adenoid enlargement in 22%.

Limitations & context

No author-stated limitations were available in the abstract. The predominantly open-label design and selected deficiency population limit interpretation beyond these children.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary